Retatrutide by Condition
Indications being studied — obesity, MASH, diabetes, sleep apnea, heart disease.
Retatrutide's TRIUMPH Phase 3 program spans far more than obesity. Eli Lilly is running registration trials across MASH, type 2 diabetes, sleep apnea, knee osteoarthritis, and cardiovascular outcomes. Here's what's been published per indication — and what's still pending.
Related topic hubs
- Trials & FDA — TRIUMPH program by indication
- Retatrutide — Retatrutide drug overview
- Safety — Condition-specific safety notes
TRIUMPH program by indication
| Indication | Trial | Status | Deep dive |
|---|---|---|---|
| Obesity (pivotal) | TRIUMPH-1 | Active — results expected 2026 | Trials tracker |
| Obesity in type 2 diabetes | TRIUMPH-2 | Active — mid-2026 | Retatrutide for T2D |
| Obesity in cardiovascular disease | TRIUMPH-3 | Active — 2026 | Heart health |
| Knee osteoarthritis | TRIUMPH-4 (N=445, 68 wks) | Complete — 28.7% weight loss, 74–76% pain reduction | TRIUMPH-4 results |
| Cardiovascular / renal outcomes | TRIUMPH-5 | Recruiting — multi-year MACE endpoints | Heart health |
| Weight maintenance | TRIUMPH-6 (N=643) | Active, no longer recruiting | — |
| MASLD / MASH (fatty liver) | TRIUMPH-MASLD | Ongoing — Phase 2 sub-study showed 81–86% liver fat reduction | Fatty liver deep dive |
| Obstructive sleep apnea | Nested sub-study in TRIUMPH-1/-2 | Awaiting parent trial readout | Sleep apnea |
By population
- Retatrutide for women — PCOS, bone density, cycle effects, contraception.
- Retatrutide for type 2 diabetes — HbA1c and weight loss data from the Phase 2 T2D trial.
- Cardiovascular effects — blood pressure, lipids, MACE outlook.
Total TRIUMPH Phase 3 enrollment is approximately 5,800 participants. Every number above is sourced in the underlying article pages.
All conditions articles
4 articles
Retatrutide and Fatty Liver Disease (MASLD/MASH)
Retatrutide produced up to 82.4% liver fat reduction in Phase 2 — among the strongest results for any drug in development for MASLD/MASH.
Updated February 2026
Retatrutide and Sleep Apnea (Obstructive Sleep Apnea)
No retatrutide OSA data yet, but the TRIUMPH-1 nested sub-study and tirzepatide's precedent point to substantial potential.
Updated June 2026
Retatrutide for Type 2 Diabetes
Retatrutide's Phase 2 T2D data showed HbA1c reductions of -2.02% and weight loss of -16.94% — with the TRANSCEND Phase 3 program underway.
Updated February 2026
Retatrutide for Women: What the Clinical Data Shows
What women need to know about retatrutide — side effects by sex, birth control interactions, fertility, hair loss, PCOS potential, and body composition.
Updated March 2026